The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

TP53 is the most frequently mutated gene in human cancer and thus an attractive target for novel cancer therapy. Several compounds that can reactive mutant p53 protein have been identified. APR-246 is currently being tested in a phase II clinical trial in high-grade serous ovarian cancer. We have us...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Oncol
Main Authors: Synnott, Naoise C., Madden, Stephen F., Bykov, Vladimir J.N., Crown, John, Wiman, Klas G., Duffy, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: Neoplasia Press 2018
Teme:
Original article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6132178/
https://ncbi.nlm.nih.gov/pubmed/30196236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.08.009
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki